Zevra Therapeutics (ZVRA) Intangibles (2023 - 2026)

Zevra Therapeutics (ZVRA) has 4 years of Intangibles data on file, last reported at $6.1 million in Q1 2026.

• Quarterly Intangibles fell 89.82% year-over-year to $6.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $6.1 million (down 89.82% YoY) and the FY2025 annual result came in at $6.4 million, down 90.69% from the prior year.
• Intangibles declined to $6.1 million in Q1 2026, from $6.4 million in the prior quarter.
• In the past five years, Intangibles ranged from a high of $69.2 million in Q4 2023 to a low of $2.0 million in Q1 2024.
• A 4-year average of $29.5 million and a median of $6.9 million in 2025 frame the typical range for Intangibles.
• The widest YoY moves for Intangibles: up 2900.0% in 2025, down 90.69% in 2025.
• Tracing ZVRA's Intangibles over 4 years: stood at $69.2 million in 2023, then declined by 0.34% to $69.0 million in 2024, then slumped by 90.69% to $6.4 million in 2025, then fell by 4.92% to $6.1 million in 2026.
• The last three Intangibles figures came in at $6.1 million (Q1 2026), $6.4 million (Q4 2025), and $6.7 million (Q3 2025), per Business Quant data.